Costs and benefits of antiemetic therapy.
Allocating part of the diminishing resources of the health-care system to new therapeutic approaches needs a decision analysis which should be understood by all partners. This paper defines some of the economic evaluation methods used recently. Through examples of cost/effectiveness and cost/benefit studies performed in the U.K. and Switzerland it shows that, in the European environment at least, specially now that prices are decreasing, serotonin-receptor (5-HT3) antagonists can and should be used to prevent acute nausea and vomiting.
Aapro
M S
MS
Divisione di Oncologia Medica, Istituto Europeo di Oncologia, Milan, Italy.
D000932:Antiemetics / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005060:Europe; D006801:Humans; D009325:Nausea / Q000517:prevention & control; D012702:Serotonin Antagonists / Q000191:economics / Q000627:therapeutic use; D013557:Switzerland; D006113:United Kingdom; D014839:Vomiting / Q000517:prevention & control
D000932:Antiemetics; D012702:Serotonin Antagonists